Status:
UNKNOWN
Role of TMEM219 Marker in Type 1 Diabetes
Lead Sponsor:
University of Milan
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
Brief Summary
Type 1 diabetes (T1D) is a chronic metabolic disease characterized by autoimmune destruction of β cells of the insulin producing pancreatic islets. The different immunological approaches implemented t...
Detailed Description
METHODS OF RECRUITING THE SUBJECTS Healthy subjects, individuals with type 1 and type 2 diabetes and those who are at risk of developing diabetes will be enrolled. Enrollment was approved by the Unive...
Eligibility Criteria
Inclusion
- Reported in the NPOD protocol
Exclusion
- Reported in the NPOD protocol
Key Trial Info
Start Date :
August 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03794739
Start Date
August 8 2020
End Date
December 1 2023
Last Update
May 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Clinical Research Center
Milan, Italy, 20157